Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 2/20 | 0.66 |
| ▸ | ITGAM | P11215 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | GSK3A | P49840 | 2/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | INSR | P06213 | 2/20 | 0.57 |
| ▸ | IGF1R | P08069 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13479551 | 0.86 | MEN1 (0.58) | ITGB2ITGAMMEN1KMT2ANPC1 | |
| SCHEMBL3895157 | 0.80 | MEN1 (0.54) | ITGB2ITGAMMEN1KMT2ARAB9A | |
| SCHEMBL3895153 | 0.80 | MEN1 (0.54) | ITGB2ITGAMMEN1KMT2ARAB9A | |
| SCHEMBL46224 | 0.79 | ITGB2 (1.00) | ITGB2ITGAMMEN1KMT2APOLB | |
| SCHEMBL14860725 | 0.79 | MAP3K5 (0.53) | ITGB2ITGAMMEN1KMT2APOLB | |
| SCHEMBL15827140 | 0.79 | MAP3K5 (0.53) | ITGB2ITGAMMEN1KMT2APOLB | |
| SCHEMBL14860726 | 0.79 | MAP3K5 (0.53) | ITGB2ITGAMMEN1KMT2APOLB | |
| SCHEMBL3892853 | 0.79 | MAPT (0.61) | ITGB2ITGAMMEN1KMT2ARAB9A | |
| SCHEMBL3892857 | 0.79 | MAPT (0.61) | ITGB2ITGAMMEN1KMT2ARAB9A | |
| SCHEMBL46548 | 0.79 | ITGB2 (0.73) | ITGB2ITGAMMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3243821-B1 | PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 | GB006 INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10239871-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2012005800-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | ADHAERE PHARAMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239871-B2 | Compounds and methods for regulating integrins | ITGA2, ITGB2, ITGA2B | ITGB2 2/4885ITGAM 9/4885MEN1 2635/4885 |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ITGB8, ITGB3, ITGAM | ITGB2 5/4885ITGAM 3/4885MEN1 1586/4885 |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | ITGB2 2/4885ITGAM 9/4885MEN1 2635/4885 |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | ITGB2 2/4885ITGAM 9/4885MEN1 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.